Phase 3 EXTENTORCH study evaluating Toripelimab plus Chemo combination in 1L ES-SCLC patients met its primary endpoint of PFS and OS

The results showed that Tori plus Chemo can significantly prolong the progression-free survival (PFS) and overall survival (OS) of ES-SCLC patients vs. chemo alone

The safety profile of Toripalimab was similar to previous studies, and no new safety signals were identified

The company plans to submit the supplemental new drug application (sNDA) for ES-SCLC soon